Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial-Reference-Cited by-同舟云学术

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

Published:2017-08 Issue:8 Volume:28 Page:1842-1848
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bamias A.,Gibbs E.,Khoon Lee C.,Davies L.,Dimopoulos M.,Zagouri F.,Veillard A.-S.,Kosse J.,Santaballa A.,Mirza M.R.,Tabaro G.,Vergote I.,Bloemendal H.,Lykka M.,Floquet A.,Gebski V.,Pujade-Lauraine E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/8/1842/19388820/mdx228.pdf

Reference22 articles.

1. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential;Luvero;Ther Adv Med Oncol,2014

2. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2013

3. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy

4. Vascular endothelial growth factor C promotes ovarian carcinoma progression through paracrine and autocrine mechanisms;Decio;Am J Pathol,2014

5. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5;Herr;Gynecol Oncol,2012

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer;Discover Oncology;2024-08-29

2. Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer;Gynecologic Oncology;2024-05

3. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer;In Vivo;2024

4. Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study;Drug Design, Development and Therapy;2023-07

5. Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis;Frontiers in Oncology;2023-06-05